New York State Common Retirement Fund’s MoonLake Immunotherapeutics MLTX Stock Holding History

New York State Common Retirement Fund’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6,992	Closed	-$273K	–	3282
2025 Q1	$273K	Buy	+6,992	New	+$301K	﹤0.01%	2105
2024 Q3	–	Sell	-140	Closed	-$6.16K	–	3286
2024 Q2	$6.16K	Sell	140 -8,126	-98%	-$344K	﹤0.01%	3245
2024 Q1	$415K	Buy	8,266 +8,175	+8,984%	+$443K	﹤0.01%	2147
2023 Q4	$5.5K	Sell	91 -74	-45%	-$3.81K	﹤0.01%	3214
2023 Q3	$9.4K	Hold	165	–	–	﹤0.01%	3219
2023 Q2	$8.41K	Buy	+165	New	+$4.44K	﹤0.01%	3271

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

New York State Common Retirement Fund's MLTX Position: Q2 2025 in Review

New York State Common Retirement Fund sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2025, closing a stake of 6,992 shares — an estimated $273K sold.

New York State Common Retirement Fund first reported a position in MLTX in Q2 2023 and held it in 6 quarters. The position peaked at $415K in Q1 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q2 2025.

New York State Common Retirement Fund reported no remaining MoonLake Immunotherapeutics position as of Q2 2025 after selling out during the quarter.
New York State Common Retirement Fund sold 6,992 MoonLake Immunotherapeutics shares in Q2 2025, an estimated $273K.
New York State Common Retirement Fund first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 6 quarters.
New York State Common Retirement Fund's MoonLake Immunotherapeutics position peaked at $415K in Q1 2024.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2025.

Based on New York State Common Retirement Fund's 13F filing for Q2 2025, filed 13 Aug 2025.